Table 1.
Patient characteristics.
| n = 16 | |
|---|---|
| Age/median [range] | 70 (60–78) |
| PSA 1/median [range] | 8.5 ng/mL (2.34–46.03 ng/mL) |
| Gleason sum/median [range] | 7 (3 + 4–4 + 50 |
| Prior Prostatectomy/number (%) | 5 (31%) |
| Prior radiation to prostate or prostatic bed | 8 (50%) |
| LHRH analog given with radiation therapy | 5 (31%) |
| De novo metastatic | 4 (25%) |
| Bone only metastases | 6 (37.5%) |
| Visceral/lung only metastases | 1 (6%) |
| Lymph node only metastases | 3 (19%) |
| Bone + lymph node metastases | 6 (37.5%) |
| High risk mCSPC 2 | 5 (31%) |
1 PSA value prior to first dose of LHRH analog for metastatic prostate cancer. 2 High risk mCSPC definition in the phase 3 LATITUDE trial [7] was used, i.e., presence of 2 of the 3 following risk factors: Gleason sum 8 or above, visceral metastases, or more than 3 bone metastases.